There are no current plans for this field to be used in the UK. Completing this box will result in the declaration going into the ‘Arrival reported’ state, and will require an ‘Arrived’ transaction to be completed by the Customs Officer at the office of destination. Note: Not to be used with multi-item declarations where more than 1 country of dispatch is declared. Ross DM, Pagani IS, Shanmuganathan N. Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells. Leukemia. 2018; 32(12):2572-2579. https://doi.org/10.1038/s41375-018-0264-0 PubMed Google Scholar

Note: Either ‘New Transport Means Identity’ and ‘New Transport Means Nationality’ or ‘new container number’ or both must be used when a transhipment has been declared. Branford S, Rudzki Z, Harper A. Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Leukemia. 2003; 17(12):2401-2409. https://doi.org/10.1038/sj.leu.2403158 PubMed Google Scholar This field must be used if an authorised consignor lodges a ‘simplified’ declaration for which the authorisation requires the use of seals, and/or the principal is authorised to use seals of a special type. First of RAF's new UK submarine hunters lands in Scotland". BBC News. 4 February 2020 . Retrieved 14 June 2020.Hanfstein B, Muller MC, Hehlmann R. Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia. 2012; 26(9):2096-2102. https://doi.org/10.1038/leu.2012.85 PubMed Google Scholar To be used only under Normal Procedure (see above), and will be completed in accordance with local practice agreed with the office of departure. Rousselot P, Charbonnier A, Cony-Makhoul P. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronicphase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. J Clin Oncol. 2014; 32(5):424-430. https://doi.org/10.1200/JCO.2012.48.5797 PubMed Google Scholar Enter the identity of the active means of transport, which, it is expected, will be used at the frontier crossing point on exit from the customs territory of the EU Nimrod MRA4 First Flight". Defence Procurement Agency. 20 September 2005. Archived from the original on 12 October 2005.

Figure 2. Patient outcomes. Flow diagram showing outcomes of 450 patients after the achievement of sustained molecular response (MR)-3 (sMR3). The boxes in the lower part of the image contain information about the tyrosine kinase inhibitor (TKI) dose at the time of response loss. LD: lower TKI dose (compared to the standard recommended doses for first or subsequent lines); SD: standard TKI dose; HD: higher TKI dose; sMR4: sustained MR4; pts: patients.Zhang J, Wang Y, Wang J. Early BCRABL1 decline in imatinib-treated patients with chronic myeloid leukemia: results from a multicenter study of the Chinese CML alliance. Blood Cancer J. 2018; 8(7):61. https://doi.org/10.1038/s41408-018-0093-4 PubMed PubMed Central Google Scholar Branford S. Molecular monitoring in chronic myeloid leukemia-how low can you go?. ASH Education Program Book. 2016; 2016(1):156-163. https://doi.org/10.1182/asheducation-2016.1.156 PubMed PubMed Central Google Scholar House of Commons Written Answers for 16 June 2010." Hansard, 16 June 2010. Retrieved: 20 October 2010. Merx K, Muller MC, Kreil S. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha. Leukemia. 2002; 16(9):1579-1583. https://doi.org/10.1038/sj.leu.2402680 PubMed Google Scholar

This field is used as a flag for an en route event which is already in NCTS, its value can be either ‘0’ = No, or ‘1’ = Yes. Enter the code for the type of the means of transport declared above. Codes are: 1=Sea, 2=Rail, 3=Road, 4=Air, 5=Post, 7=Fixed transport installation, 8=Inland waterway and 9=Own propulsion. Kim D, Hamad N, Lee HG, Kamel-Reid S, Lipton JH. BCR/ABL level at 6 months identifies good risk CML subgroup after failing early molecular response at 3 months following imatinib therapy for CML in chronic phase. Am J Hematol. 2014; 89(6):626-632. https://doi.org/10.1002/ajh.23707 PubMed Google Scholar Note: Not to be used with multi-item declarations where more than 1 country of destination is declared.Enter type of declaration, for example, T1/T2/T2SM (for goods destined to San Marino) /T2F/ TIR. If the goods are of mixed status, for example, T1 and T2, use T- in the header information, and specify the status of the individual items.

patients were included from Dec/2016 until Oct/2017. Median age was 54years, 58 % male, 58 % low Sokal, 65 % b3a2 transcripts, and 61 % were in MR4.5. Imatinib therapy's median time was 9.7y (3-14.9 y), median time of MR4 was 6.9y (1.6-10.3y). MRFS at 24 months was 55 % (95 % CI 39-75). Thirteen patients relapsed, 46 % after six months of discontinuation, and all patients recovered MMR. Median time to recover MMR was one month. MR4.5 was the only factor associated with MRFS. NK cells proportion at baseline was lower in patients with only MR4 who relapsed after discontinuation. The molecular response levels use defined cut-off values and the inherent variability of the quantitative PCR assay means there will be fluctuations above or below the cut-off values. 61 , 62 These fluctuations will be greater at low levels of BCR-ABL1. However, in some cases, fluctuations are an indication of subsequent relapse. A study of 208 patients treated with imatinib as their first-line therapy investigated the outcome of patients with fluctuating BCR-ABL1 values according to the level of response achieved. 63 A stable molecular response was defined as persistence of the same molecular response (MMR, MR4 or MR4.5) at three consecutive assessments. A fluctuation was the achievement of the molecular response and its subsequent loss. For patients who had not yet achieved DMR but had achieved MMR, 12.6% had at least one fluctuation. These patients had a significantly poorer failure- free survival compared to patients with no fluctuation: 82.4% versus 93.2%, respectively. Of patients with DMR and fluctuations, none acquired resistance or BCRABL1 kinase domain mutations. This study demonstrated that unstable MMR was associated with an increased risk of imatinib resistance, whereas fluctuations of deeper molecular responses did not influence outcome. 63 Fava C, Rege-Cambrin G, Dogliotti I. Early BCR-ABL1 reduction is predictive of better event-free survival in patients with newly diagnosed chronic myeloid leukemia treated with any tyrosine kinase inhibitor. Clin Lymphoma Myeloma Leuk. 2016; 16:S96-S100. https://doi.org/10.1016/j.clml.2016.03.008 PubMed Google Scholar Enter the individual identification number of each of the seals used for the consignment. For conditions – see above. Pagnano KBB. BCR-ABL1 level monitoring in chronic myeloid leukemia by real time polymerase chain reaction in Brazil - not so real. Rev Bras Hematol Hemoter. 2017; 39(3):197-198. https://doi.org/10.1016/j.bjhh.2017.05.005 PubMed PubMed Central Google ScholarShah NP, Garcia-Gutierrez V, Jimenez-Velasco A. Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study. Leuk Lymphoma. 2020; 61(3):650-659. https://doi.org/10.1080/10428194.2019.1675879 PubMed Google Scholar Muller MC, Erben P, Saglio G. Harmonization of BCR-ABL mRNA quantification using a uniform multifunctional control plasmid in 37 international laboratories. Leukemia. 2008; 22(1):96-102. https://doi.org/10.1038/sj.leu.2404983 PubMed Google Scholar